Pain, dyspnea, and anorexia are common symptoms experienced by patients with cancer and often are poorly managed.
Methods
The incidence and causes of these symptoms are described, as well as factors that exacerbate or ameliorate their impact.
Results
Pharmacologic management of cancer pain is based on the use of a sequential “ladder” that incorporates nonopioid, opioid, and adjuvant drugs, depending on the severity of the pain. This approach usually is effective. Other symptoms of advanced disease may be more difficult to control.
Conclusions
Adherence to an adequate pain-control strategy will significantly enhance palliation of pain in patients with cancer.
Get full access to this article
View all access options for this article.
References
1.
Cancer Pain Relief and Palliative Care. Report of a WHO Expert Committee. World Health Organization Technical Report Series 804; World Health Organization, Geneva, Switzerland, 1990.
2.
BonicaJ.J.Cancer pain. In: BonicaJ.J., ed. The Management of Pain. Vol 1. 2nd ed.Philadelphia, Pa: Lea and Febiger; 1990: 400–460.
3.
DautR.L., CleelandC.S.The prevalence and severity of pain in cancer. Cancer.1982; 50: 1913–1918.
4.
LarueF., ColleauS.M., BrasseurL.Multicentre study of cancer pain and its treatment in France. Br Med J.1995; 310: 1034–1037.
5.
FoleyK.M.The treatment of cancer pain. N Engl J Med.1985; 313: 84–94.
6.
FoleyK.M.Pain syndromes in patients with cancer. Med Clin North Am.1987; 71: 169–184.
7.
PortenoyR.K.Diagnosis of cancer pain syndromes. In: FieldsH.L., ed. Pain Syndromes in Neurology.London: Butterworths; 1990: 239–255
8.
PattR.B.Classification of cancer pain and cancer pain syndromes. In: PattR.B., ed. Cancer Pain.Philadelphia, Pa: JB Lippincott Co; 1993: 3–22.
9.
International Association for the Study of Pain. Subcommittee on Taxonomy. Classification of chronic pain: descriptors of chronic pain syndromes and definition of pain terms. Pain.1986; 3: S1–S225.
10.
Cancer Pain Relief.Geneva: World Health Organization; 1986.
11.
CleelandC.S., GoninR., HatfieldA.K.Pain and its treatment in outpatients with metastatic cancer. N Engl J Med.1994; 330: 592–596.
12.
ZenzM., ZenzT., TrybaM.Severe undertreatment of cancer pain: a 3-year survey of the German situation. J Pain Symptom Manage.1995; 10: 187–191.
13.
VentafriddaV., TamburiniM., CaraceniC.A validation study of the WHO method for cancer pain relief. Cancer.1987; 59: 850–856.
14.
ZechD.F.J., GrondS., LynchJ.Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain.1995; 63: 65–76.
15.
JadadA.R., BrowmanG.P.The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA.1995; 274: 1870–1873.
16.
EisenbergE., BerkeyC.S., CarrD.B.Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol.1994; 12: 2756–2765.
17.
BeaverW.T.Nonsteroidal antiinflammatory analgesics in cancer pain. In: FoleyK.M., ed. Advances in Pain Research and Therapy.New York, NY: Raven Press; 1990: 109–131.
18.
PilettaP., PorchetH.C., DayerP.Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther.1991; 49: 350–354.
19.
WillerJ.C., De BrouckerT., BusselB.Central analgesic effect of ketoprofen in humans: electrophysiological evidence for a supraspinal mechanism in a double-blind and cross-over study. Pain.1989; 38: 1–7.
20.
BjorkmanR., UllmanA., HednerJ.Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol.1993; 44: 1–5.
21.
StambaughJ.E.Role of nonsteroidal anti-inflammatory drugs in the management of cancer pain. In: PattR.B., ed. Cancer Pain.Philadelphia, Pa: JB Lippincott Co; 1993: 105–117.
22.
De ConnoF., RipamontiC., SbanottoA.A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage.1991; 6: 423–427.
23.
GlareP.A., WalshT.D.Clinical pharmacokinetics of morphine. Ther Drug Monit.1991: 13: 1–23.
24.
FinnJ.W., WalshD., MacDonaldN.Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulphate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol.1993; 11: 967–972.
25.
De ConnoF., RipamontiC., SaitaL.Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol.1995; 13: 1004–1008.
26.
BrueraE., BrenneisC., MichaudM.Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer.1988; 62: 407–411.
27.
De ConnoF., RipamontiC., TicozziC.Intraspinal opioids and local anaesthetics for cancer pain. Eur J Palliat Care.1994; 1: 162–168.
28.
MoulinD.E., KreeftJ.H., Murray-ParsonsN.Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet.1991; 337: 465–468.
29.
SaweJ., HansenJ., GinmanC.Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J (Clin Res Ed).1981; 282; 771–773.
30.
VentafriddaV., RipamontiC., BianchiM.A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage.1986; 1: 203–207.
31.
BrueraE., WatanabeS., FainsingerR.L.Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain.1995; 62: 141–146.
32.
RipamontiC., ZeccaE., BrunelliC.Rectal methadone in cancer patients with pain: a preliminary clinical and pharmacokinetic study. Ann Oncol.1995; 6: 841–843.
33.
GrochowL., SheidlerV., GrossmanS.Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain.1989; 38: 151–157.
34.
BrueraE., FainsingerR.L., MooreM.Local toxicity with subcutaneous methadone: experience of two centers. Pain.1991; 45: 141–143.
35.
HuntG., BrueraE.Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage.1995; 10: 401–404.
36.
The tole of the fentanyl series for pain management: novel delivery systems. J Pain Symptom Manage.1992; 7(Suppl 3): S1–S62.
37.
MiserA.W., NarangP.K., DothageJ.A.Transdermal fentanyl for pain control in patients with cancer. Pain.1989; 37: 15–21.
38.
de StoutzN.D., BrueraE., Suarez-AlmazorM.Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage.1995; 10: 378–384.
39.
BrueraE., RipamontiC.Adjuvant to opioid analgesics. In: PattR.B., ed. Cancer Pain.Philadelphia, Pa: JB Lippincott Co; 1993: 143–159.
40.
WatsonC.P., EvansR.J., ReedK.Amitryptiline versus placebo in postherpetic neuralgia. Neurology.1982; 32: 671–673.
PaneraiA.E., MonzaG., MoviliaP.A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand.1990; 82: 34–38.
43.
SindrupS.H., EjlertsenB., FrolandA.Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol.1989; 37: 151–153.
44.
SindrupS.H., GramL.F., SkjoldT.Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind crossover study. Br J Clin Pharmacol.1990; 30: 683–691.
45.
MaxM.B., LynchS.A., MuirJ.Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med.1992; 326: 1250–1256.
46.
WalshT.D.Controlled study of imipramine and morphine in chronic pain due to cancer. Proc Annu Meet Am Soc Clin Oncol.1986; 5: 237. Abstract.
47.
FeinmanC.Pain relief by antidepressants: possible modes of action. Pain.1985; 23: 1–8.
48.
VentafriddaV., RipamontiC., De ConnoF.Antidepressants increase bioavailability of morphine in cancer patients. Lancet.1987; 333: 1204.
49.
VentafriddaV., BianchiM., RipamontiC.Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain.1990; 43: 155–162.
50.
LiuS.J., WangR.I.Increased analgesia and alterations in distribution and metabolism of methadone by desipramine in the rat. J Pharmacol Exp Ther.1975; 195: 94–104.
51.
GreenbergH.S., KimJ.H., PosnerJ.B.Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol.1980; 8: 361–366.
52.
VechtChJ, Haaxma-ReicheH., van PuttenW.L.J.Initial bolus of conventional versus high-dose dexamethazone in metastatic spinal cord compression. Neurology.1989; 39: 1255–1257.
53.
ShellH.Adrenal corticosteroid therapy in far-advanced cancer. Geriatrics.1972; 27: 131–141.
54.
BrueraE., RocaE., CedaroL.Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep.1985; 69: 751–754.
55.
Della CunaG.R., PellegriniA., PiazziM.Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. Eur J Cancer Clin Oncol.1989; 25: 1817–1821.
PopielaT., LucchiR., GiongoF.Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol.1989; 25: 1823–1829.
58.
StiefelF.C., BreitbartW.S., HollandJ.C.Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest.1989; 7: 479–491.
59.
SwerdlowM.The use of anticonvulsants in the management of cancer pain. In: ErdmannW., OyammaT., PernakM.J., eds: The Pain Clinic. Vol 1. Utrecht, The Netherlands: VNU Science Press; 1985: 9–15.
60.
SweetW.H.Treatment of trigeminal neuralgia (tic douloureux). N Engl J Med.1986; 315: 174–177.
61.
MarchettiniP., LacerenzaM., MarangoniC.Lidocaine test in neuralgia. Pain.1992; 48: 377–382.
62.
KastrupJ., PetersonP., DejgardA.Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy. Pain.1987; 28: 69–75.
63.
BachF.W., JensenT.S., KastrupJ.The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain.1990; 40: 29–34.
64.
FerranteF.M., PaggioliJ., CherukuriS.The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg.1996; 82: 91–97.
65.
GalerB.S., MillerK.V., RowbothamM.C.Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology.1993; 43: 1233–1235.
66.
BroseW.G., CousinsM.J.Subcutaneous lidocaine for the treatment of neuropathic cancer pain. Pain.1991; 45: 145–148.
67.
EllemannK., SjogrenP., BanningA.M.Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain.1989; 5: 291–294.
68.
BrueraE., RipamontiC., BrenneisC.A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage.1992; 7: 138–140.
69.
DejgardA., PetersonP., KastrupJ.Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet.1988: 1: 9–11.
70.
ChabalC., JacobsonL., MarianoA.The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology.1992; 76: 513–517.
71.
LindstromP., LindblomU.The analgesic effect of tocainide in trigeminal neuralgia. Pain.1987; 28: 45–50.
72.
Lie -A-HuenL., ProostJ.H., KingmaJ.H.Absorption kinetics of oral and rectal flecainide in healthy subjects. Eur J Clin Pharmacol.1990; 38: 595–598.
73.
BoonenkampP.M., van der Wee-PalsL.J.A., van Wijk-van LennepM.M.Two models of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner.1986; 1: 27–39.
74.
MillwardM.J., CantwellB.M.J., CarmichaelJ.A randomized trial of the addition of disodium pamidronate (APD) to endocrine therapy for advanced breast cancer with bone metastases. Proc Annu Meet Am Soc Clin Oncol.1991; 10: A42.
75.
BerensonJ.R., LichtensteinA., PorterL.Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med.1996; 334: 488–493.
76.
LiptonA., GloverD., HarveyH.Pamidronate in the treatment of bone metastasis: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol.1994; 5: S31–S35.
77.
ConteP.F., GiannessiP.J., LatreilleJ.Delayed progression of bone metastasis with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol.1994; 5: S41–S44.
78.
van Holten-VerzantvoortA.T.M., KronH.M., BijvoetO.L.M.Palliative pamidronate treatment in patient with bone metastases from breast cancer. J Clin Oncol.1993; 11: 491–498.
79.
ThurlimannB., MorantR., JungiW.F.Pamidronate for pain control in patients with malignant osteolytic disease: a prospective dose-effect study. Support Care Cancer.1994; 2: 61–65.
80.
HigginsonI., McCarthyM.Measuring symptoms in terminal cancer: are pain and dyspnoea controlled?J R Soc Med.1989; 82: 264–267.
81.
ReubenD.B., MorV.Dyspnea in terminally ill cancer patients. Chest.1986; 89: 234–236.
82.
MuersM.F., RoundC.E.Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax.1993; 48: 393–343.
83.
BrueraE., de StoutzN., Velasco-LeivaA.Effects of oxygen on dyspnea in hypoxemic terminal cancer patients. Lancet.1993; 342: 13–14.
84.
BrueraE., SchoellerT., MacEachernT.Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage.1992; 7: 365–368.
85.
WoodcockA.A., GrossE.R., GellertA.Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med.1981; 305: 1611–1616.
86.
LightR.W., MuroJ.R., SatoR.I.Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis.1989; 139: 126–133.
87.
BrueraE., MacEachernT., RipamontiC.Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med.1993; 119: 906–907.
88.
CohenM.H., AndersonA.J., KrasnowS.H.Continuous intravenous infusion of morphine for severe dyspnea. South Med J.1991; 84: 229–234.
89.
FrewA.J., HolgateS.T.Clinical pharmacology of asthma: implications for treatment. Drugs.1993; 46: 847–862.
90.
MurcianoD., AubierM., LecocguicY.Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med.1984; 311: 349–353.
BrueraE., MacDonaldR.N.Nutrition in cancer patients: an update and review of our experience. J Pain Symptom Manage.1988; 3: 133–140.
93.
BrueraE., CatzZ., HopperR.Chronic nausea and anorexia in advanced cancer patients: a possible role for autonomic dysfunction. J Pain Symptom Manage.1987; 2: 19–21.
94.
DewysW.D., BeggC., LavinP.T.Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med.1980; 69: 491–497.
95.
KoretzR.Parenteral nutrition: is it oncologically logical?J Clin Oncol.1984; 2: 534–538.
96.
LoprinziC.L., MichalakJ.C., SchaidD.J.Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol.1993; 11: 762–767.
97.
BrueraE., MacmillanK., KuehnN.A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer.1990; 66: 1279–1282.
98.
BrueraE., BrenneisC., MichaudM.Continuous subcutaneous infusion of metoclopramide using a portable disposable pump. Ann Intern Med.1986; 104: 896–897.
